Drug-eluting stents for treatment of coronary artery disease
Record ID 32008000012
English
Authors' objectives:
Drug-eluting stents (DES) are used for the minimally invasive treatment of coronary artery obstruction in patients with symptomatic coronary artery disease (CAD) who require percutaneous coronary angioplasty and stenting. Basically, a DES is a bare-metal stent (BMS) that is coated with an antiproliferative or immunomodulatory drug, which is released gradually into the arterial wall to suppress scar tissue formation within the stent and adjacent areas. The goals of treatment are to reduce the incidence of in-stent restenosis (ISR), symptom recurrence, and other complications, and, thereby, reduce the need for repeat percutaneous or surgical revascularization.
Authors' methods:
Review
Details
Project Status:
Completed
URL for project:
http://www.hayesinc.com/
Year Published:
2007
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Drug-Eluting Stents
- Coronary Artery Disease
Contact
Organisation Name:
HAYES, Inc.
Contact Address:
157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name:
saleinfo@hayesinc.com
Contact Email:
saleinfo@hayesinc.com
Copyright:
HAYES, Inc.
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.